MARKET

HOWL

HOWL

Werewolf Therapeutics, Inc.
NASDAQ
0.8892
+0.4580
+106.22%
Opening 11:15 08/21 EDT
OPEN
0.9832
PREV CLOSE
0.4312
HIGH
1.050
LOW
0.8624
VOLUME
215.65M
TURNOVER
--
52 WEEK HIGH
2.380
52 WEEK LOW
0.2700
MARKET CAP
43.21M
P/E (TTM)
-1.2124
1D
5D
1M
3M
1Y
5Y
1D
Dow Jumps 350 Points; BJ's Wholesale Club Posts Upbeat Earnings
Benzinga · 1h ago
Werewolf Therapeutics Takes Aim At Untapped Pain Market With Ambros Deal
Benzinga · 1h ago
One of Israel Englander's Biotech Picks Just Turned Into a $500M Merger Story
Benzinga · 1h ago
Werewolf Therapeutics to Merge and Rebrand as Ambros
TipRanks · 1h ago
Why Is Penny Stock Werewolf Therapeutics (HOWL) Up Today?
TipRanks · 2h ago
Morning Movers: BJ’s Wholesale gains following second quarter earnings
TipRanks · 2h ago
Werewolf Therapeutics Shares Leap on Reverse Merger, Asset Sale
Dow Jones · 2h ago
Werewolf Therapeutics And Ambros Therapeutics Announce Merger; Secure $150M Financing
NASDAQ · 2h ago
More
About HOWL
Werewolf Therapeutics, Inc. is a biopharmaceutical company engaged in the development of therapeutics engineered to stimulate the body’s immune system for the treatment of cancer and other immune-mediated conditions. It is leveraging its PREDATOR platform to design conditionally activated molecules that stimulate both adaptive and innate immunity with the goal of addressing the limitations of conventional proinflammatory immune therapies. Its INDUKINE molecules are intended to remain inactive in peripheral tissue yet activate selectively in the tumor microenvironment. The Company’s advanced clinical-stage product candidates, WTX-124 and WTX-330, are systemically delivered, conditionally activated Interleukin-2 (IL-2) and IL-12 INDUKINE molecules for the treatment of solid tumors. It is advancing WTX-124 in multiple tumor types as a single agent and in combination with an immune checkpoint inhibitor. It is advancing WTX-712, WTX-518, and WTX-921 through preclinical development.

Webull offers Werewolf Therapeutics Inc stock information, including NASDAQ: HOWL real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, HOWL stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading HOWL stock methods without spending real money on the virtual paper trading platform.